SDCVF yields 2.82% · JNJ yields 2.13%● Live data
📍 SDCVF pulled ahead of the other in Year 1
Combined, SDCVF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SDCVF + JNJ for your $10,000?
Vicat S.A. produces and sells cement, ready-mixed concrete, and aggregates. The company operates in three segments: Cement, Concrete & Aggregates, and Other Products & Services. It offers various cement products, including Portland cement, Portland composite cement, blast furnace cement, slag cement, and Pozzolan cement for the general contractors, such as concrete mixers; manufacturers of precast concrete products; construction and public works contractors; local authorities; residential property developers or master masons; and construction material wholesalers or retail chains. The company also provides ready-mixed concrete comprising standard and special concrete for the construction and public works contractors, including construction groups, house building companies, farmers, or private individuals, as well as industrial, commercial buildings, roads, bridges, tunnels, and highways; aggregates, such as sands and gravel products for the ready-mixed concrete and precast concrete products manufacturers. In addition, it offers construction chemicals for use in exterior wall coatings, mortar and traditional concretes, tiling adhesives, and thermal insulation products, as well as for the products used to repair floors and walls; adhesives, and paper bags for the agro-food, chemical, and construction sectors. Further, the company provides various services comprising logistics, transportation, and distribution. It operates in France, Switzerland, Italy, the United States, Turkey, Egypt, Senegal, Mali, Mauritania, Kazakhstan, India, and Brazil. Vicat S.A. was incorporated in 1853 and is headquartered in L'Isle-d'Abeau, France.
Full SDCVF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.